The incretin-based drugs glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, are both used as glucose-lowering therapy for type 2 diabetes mellitus [2, 3]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.